Refocus Group, Inc. (RFCS) Research

Refocus Group, Inc. is a medical technology firm dedicated to the research and creation of therapies for various human vision conditions, particularly presbyopia. A key offering is the VisAbility Micro-Insert System, an experimental medical device currently undergoing clinical evaluations for its application in treating presbyopia affecting both eyes. The organization caters to the needs of both patients and ophthalmic professionals. Founded in 1994, this company operates from its base in Dallas, Texas.

Market snapshot

Symbol
RFCS
Price
$0.00
Day change
0.00%
Market cap
$25.0
52-week range
1.0E-6-1.0E-6
Sector
Healthcare
Industry
Medical - Devices

Recent news

  • OpenAI Plans Launch of Desktop ‘Superapp' to Refocus, Simplify User Experience

    The AI company will combine ChatGPT, Codex app and browser in an effort to focus and streamline its resources.

Peer companies

  • Primo Nutraceuticals Inc. (BUGVF)
  • The Greenrose Holding Company Inc. (GNRS)
  • Green Hygienics Holdings Inc. (GRYN)
  • LifeHOUSE Holdings, LLC (LHRP)
  • QMed, Inc. (QMED)
  • Response Oncology, Inc. (ROIX)
  • Synvista Therapeutics, Inc. (SYNI)
  • VeriTeQ Corporation (VTEQ)

Open Refocus Group, Inc. (RFCS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.